BlockBeats News, March 8, the Longgang District of Shenzhen AI (Robot) Office issued the "Several Measures to Support the Development of OpenClaw&OPC in Longgang District, Shenzhen (Draft for Comments)" for public opinion. It proposed to encourage the market-oriented, specialized platform to launch the "Lobster Service Area," provide free OpenClaw deployment services, and give certain subsidies to eligible entities; provide support for the development and promotion of OpenClaw-like intelligent agent tools. For those who contribute key code to the international mainstream community, list Longgang advantage industry-related skill packages on the skills trading platform, and develop application projects combining with embodied intelligent devices, once recognized, they will receive a maximum subsidy of 2 million RMB.
Focus on intelligent manufacturing, smart government affairs, smart parks, smart healthcare, and other fields, select a group of innovative and effective OpenClaw in-depth application projects every year, award them the title of "Longgang District OpenClaw Application Demonstration Project," and provide a one-time reward of up to 1 million RMB based on actual investment, up to 30%. Provide investment and financing channels for seed-stage OPC projects with high technological content and strong innovation capabilities (focus on supporting youth entrepreneurship projects), and give a maximum of 10 million RMB in equity investment support to eligible ones.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.


















Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.











